Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Stephen R.D. Johnston, MD, PhD, on Clinical Considerations When Prescribing Abemaciclib for Early Breast Cancer

Posted: Tuesday, September 29, 2020

Stephen R.D. Johnston, MD, PhD, of The Royal Marsden NHS Foundation Trust, talks about selecting patients and managing their long-term adverse events when prescribing abemaciclib for hormone receptor–positive high-risk early breast cancer—the first CDK4/6 inhibitor to improve invasive disease–free survival.

For more on this study, visit the Journal of Clinical Oncology.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.